Accelerate Diagnostics Preliminary FY23 Revenue Down
(RTTNews) - Accelerate Diagnostics Inc. (AXDX) reported that its preliminary revenue for the fiscal year 2023 declined to about $12.1 million from last year's $12.8 million, due to a challenging capital sales environment in all sales regions.
Annual revenues for consumable products increased by approximately 5% from the previous year.
The company said it secured approximately 65% of current U.S. Pheno customers to multi-year contracts for rapid susceptibility testing, reflecting customers' commitment to Accelerate rapid AST technology and interest in Wave.
Accelerate expects to announce full-year 2023 financial results in advance of itsearnings conference callin March 2024.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.